This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Free Online Activities

Series Introduction and Cardiovascular Disease in Patients With Schizophrenia

Charles H. Hennekens, MD, and John W. Newcomer, MD

Published: May 15, 2007

Article Abstract

Because this piece does nothave an abstract, we have provided for your benefit the first 3 sentencesof the full text.

Persons with schizophrenia and other mental illnessexperience a markedly shorter life expectancy than the general population. Althoughthis difference has often been attributed to suicide, cardiovascular disease isin fact the leading cause of death for patients with mental illness.Cardiovascular disease, which is also the leading cause of death for thegeneral population in the United States, is projected to become the worldwideleading cause of death by 2020. Risk factors for cardiovascular disease includeobesity, high blood cholesterol, high blood pressure, diabetes, and cigarettesmoking. Patients with schizophrenia experience high rates of cardiovasculardisease in part because they have higher rates of obesity, dyslipidemia,diabetes, and smoking. In addition to treating the psychiatric conditions ofpatients, clinicians should particularly monitor their patients for cardiovascularrisk.

See entire activity‘ ‹’ ‹

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 68

Quick Links: Schizophrenia and Schizoaffective Disorders

Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...